Date: July 21, 2026

Financial Performance Overview

Anthem Biosciences Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026 (Q1FY27).

Revenue Analysis

Consolidated Revenue from Operations for Q1FY27 stood at ₹4,182 Mn, a decrease of 22.6% Year-over-Year (YoY) from ₹5,402 Mn in Q1FY26. Sequentially, revenue decreased 31.5% from ₹6,109 Mn in Q4FY26.

The revenue is broken down into two segments:

  • CRDMO business: ₹3,408 Mn (Q1FY26: ₹4,527 Mn, -24.7% YoY; Q4FY26: ₹5,128 Mn, -33.5% QoQ)
  • Specialty Ingredients: ₹774 Mn (Q1FY26: ₹875 Mn, -11.5% YoY; Q4FY26: ₹981 Mn, -21.1% QoQ)

Other Income for the quarter was ₹249 Mn, an increase of 9.2% from ₹228 Mn in Q1FY26. This resulted in Total Revenues of ₹4,431 Mn for Q1FY27.

A detailed breakdown of Other Income was provided:

  • Other Operating Income (forex gain net and RoDTEP incentives): ₹13 Mn (Q1FY26: ₹37 Mn)
  • Financial and other Non-Operating Income: ₹236 Mn (Q1FY26: ₹191 Mn)

Profitability Metrics

EBITDA for Q1FY27 was ₹1,755 Mn, compared to ₹2,143 Mn in Q1FY26, representing an 18.1% decline YoY. EBITDA margins were 39.6%.

Profit Before Tax (PBT) before exceptional items was ₹1,446 Mn, a decrease of 22.4% from ₹1,862 Mn in Q1FY26. There were no exceptional items in Q1FY27 or Q1FY26. Profit Before Tax after exceptional items was also ₹1,446 Mn.

Profit After Tax (PAT) was ₹1,199 Mn, an increase of 11.7% from ₹1,358 Mn in Q1FY26. PAT margins were 27.1%.

Full-Year FY26 Reference Data

The press release included full-year FY26 figures for context:

  • Revenue from Operations: ₹21,243 Mn
  • Total Revenues: ₹22,801 Mn
  • EBITDA: ₹9,896 Mn
  • Profit before tax before exceptional items: ₹8,486 Mn
  • Exceptional Items: ₹244 Mn (impact)
  • Profit before tax after exceptional items: ₹8,242 Mn
  • Profit after tax: ₹5,918 Mn

Management Commentary

Ajay Bhardwaj, Chairman, MD and CEO, commented on the results. He stated that the Q1FY27 results reflect timing shifts in deliveries to key customers but affirmed that underlying demand remains strong. He expects a higher concentration of scheduled deliveries in the latter half of the year, positioning the company to capture momentum and sustain revenue growth aligned with its long-term historical performance.

On margins, he noted a year-on-year improvement across both EBITDA and PAT margins. This was attributed to a disciplined focus on cost efficiencies, yield optimization, and employee productivity, which reinforces the company's industry-leading margin profile. The management is positioned to sustain this performance through the year.

Earnings Call Details

The company will conduct an earnings call on July 22, 2026, at 11:30 am IST to discuss the financial and business performance of the quarter. Dial-in numbers were provided for universal and international access, along with a Diamond Pass registration link.

Company Background

The press release reiterates that Anthem is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with integrated operations spanning drug discovery, development, and manufacturing. It highlights its capabilities in both New Chemical Entities (NCE) and New Biological Entities (NBE).